Background: COVID-19 infection prognosis is known to worsen in patients with various co-morbidities particularly with uncontrolled diabetes mellitus and is often associated with increased serum levels of various inflammatory markers such as CRP, IL-6, D-dimer, LDH etc. Hence optimal glycemic care is crucial for a good prognosis in type 2 Diabetes (T2D) patients with COVID-19 infection. Efficacy and safety of Empagliflozin/linagliptin fixed dose combination (FDC) in T2D patients is well known. In the present study, the safety and effectiveness of Empagliflozin/Linagliptin FDC was evaluated in T2D patients diagnosed with COVID-19 infection.

Aim: To evaluate the safety, effectiveness of T2D patients with COVID-19 infection with empagliflozin/linagliptin FDC.

Methods: A single center, retrospective observational study included T2D patients who were on Empagliflozin/Linagliptin (25/5 mg) at the time of COVID-19 diagnosis and were followed up for 6 months. Laboratory (HbA1c, Ferritin, LDH, IL-6, CRP, D-Dimer) and clinical assessments (need for oxygen support & steroids) were done at baseline, 3rd, and 6th months. Repeated measures ANOVA was used to determine the mean difference at specified time intervals and any p-value < 0.05 was considered statistically significant.

Results: A total of 50 T2D patients were included with mean age (SD) was 57.44 ± 9.88 years. Patients treated with Empagliflozin/Linagliptin FDC at 6 months showed significant reduction in HbA1c (6.87 ± 0.22 mg/dL from 10.2± 0.9 mg/dL), CRP (8.9 ± 2.79 mg/dL from 99.2 ± 4.00 mg/dL), LDH (288 ± 45.12U/L from 675 ± 95.41U/L), ferritin (408.4 ± 131.00 ng/mL from 1100± 216.2 ng/mL), IL-6 (8.97 ± 2.40 pg/mL from 95.56 ± 23.4 pg/mL). Also, the need for oxygen support and daily steroid dose requirement had become lesser over 6 months.

Conclusion: Once daily Empagliflozin/Linagliptin (25/5 mg) FDC was found to be safe, effective, and well tolerated in non-critically ill T2D patients with COVID-19 infection.

Disclosure

A.Sengupta: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.